Howard Robin Nektar Therapeutics CEO Rating

Nektar Therapeutics CEO Howard Robin Bio

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Therapeutics since January 15, 2007. From January 2001 to June 2001, he served as Chief Operating Officer and President of Prime Holdings & Investments Inc. He served as President and Chief Executive Officer of Sirna Therapeutics, Inc. since July 2001. Prior to Sirna Therapeutics, Inc., he served in a variety of functions during 20 years at Berlex Laboratories. From 1991 to 2001, Mr. Robin served as Corporate Vice President and General Manager of Berlex Laboratories Inc. From 1987 to 1991, he served as Vice President of Finance & Business Development and Chief Financial Officer of Berlex Laboratories Inc. From 1984 to 1987, he served as Director of Business Planning & Development at Berlex. Prior to Berlex, he served as a Senior Associate with Arthur Andersen & Company prior to joining Berlex. Mr. Robin has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. He serves as a Director of Acologix, Inc. He has been a Director of Nektar Therapeutics since February 14, 2007. Mr. Robin has been a Director of Sirna Therapeutics Inc. since July 2001. He served as a Director of Bay Area Bioscience Association. Previously, He served as a Director of Prime Holdings & Investments from January 2001 to June 2001. He received his B.S. in Accounting & Finance from Farleigh Dickinson University in 1974.

Nektar Therapeutics CEO Howard Robin At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Nektar Therapeutics.

Based on 8 ratings, Howard Robin ranks right below Genentech's CEO, Alexander Hardy.

Overall, the CEO score has remained stable over the last 90 days.